ORIC manages and monitors externally funded research projects undertaken by the faculty of Shaheed Zulfiqar Ali Bhutto Medical University.
| # | Research Project | Funding Agency | Principal Investigator | Grant Amount | Status |
|---|---|---|---|---|---|
| 1 | Identification of molecular determinants of hereditary deafness | PSF Pakistan | Dr Mohsin Shahzad | PKR 4.2 Million | Ongoing |
| 2 | Molecular and Epidemiology determinants of Breast Cancer | HEC Pakistan | Dr Asmat Ullah | PKR 0.5 Million | |
| 3 | Functional Characterization of two Novel Intellectual Disability genes, DCTN2 and METTL5 | HEC Pakistan | Dr Mohsin Shahzad | PKR 4.2 Million | |
| 4 | Genetic Characterization of Cognaitive Disability in Pakistani Population | HEC Pakistan | Prof. Dr Javed Akram | PKR 8.6 Million | |
| 5 | Prevalence of TP53 germline mutations in Breast cancer affected patients of Pakistan | HEC Pakistan | Dr Syeda Kiran Riaz | PKR 0.5 Million | |
| 6 | Unraveling the genetic molecular landscape of high grade gliomas in Pakistani patients | HEC Pakistan | Dr Saboora Waris | PKR 0.5 Million | |
| 7 | Development of Artificial Intelligence based CADx system for rapid diagnosis of COVID-19 patients using Chest X-Ray (CXR) and Computed Tomography (CT) scans alongside RT-PCR | PSF Pakistan | Prof. Dr Ayesha Isani Majeed | ||
| 8 | Genetic characterization of Prevalent Ophthalmic Disorders in Pakistan | HEC Pakistan | Dr. Waqar Arshad | PKR 1 Million | |
| 9 | A Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Bemnifosbuvir in high-risk outpatients with Covid -19 | ATEA USA | Prof. Dr Tanwir Khaliq | ||
| 10 | A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants | Gates and Melinda USA | Prof. Dr Tanwir Khaliq Prof. Dr. Maqbool Hussain |
||
| 11 | A prospective cohort study investigating maternal, pregnancy and neonatal outcomes for women and neonates infected with SARS-CoV-2 | World Health Organization (WHO), Geneva | Dr. Syeda Kiran Riaz | ||
| 12 | A Randomized, Double-Blind Clinical Study of the Efficacy and Safety of BCD-201 (JSC BIOCAD) and Keytruda® in Patients with Unresectable or Metastatic Melanoma | Biocad Biotechnology Company, Russia | Prof. Dr. Tanwir Khaliq Dr. Qasim M. Buttar |
||
| 13 | Application of Artificial Intelligence in Vascular Disease Management | National Centre for Artificial Intelligence (NCAI)-HEC, Pakistan | Prof. Dr. Tanwir Khaliq | Completed | |
| 14 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk outpatients with Covid-19 | Prof. Dr Tanwir Khaliq |